People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Biotechnology, Other Technology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TheRas, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.3B | 2024 |
| Garuda Therapeutics, Inc. | — | Biotechnology | Series C | $158.0M | $380.2M | 2024 |
| BiVACOR Inc. | — | Other Technology | Series A | $24.0M | $48.3M | 2023 |
| Kamau Therapeutics, Inc. | — | Pharma | Series A | $5.0M | $17.4M | 2025 |
Raymond Kelleher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Raymond Kelleher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| BIHUA CHEN | 1 | 14 |
| Frank McCormick | 1 | 7 |
| Paul Kelly | 1 | 5 |
| Raymond W. Cohen | 1 | 5 |
| Neil Kumar | 1 | 3 |
| Michelle Doig | 1 | 3 |
| Steve Liapis | 1 | 3 |
| Eric Aguiar | 1 | 3 |
| Matthew Porteus | 1 | 2 |
| Valentin Barsan | 1 | 2 |
| William E. Cohn | 1 | 2 |
| Shaan I Gandhi | 1 | 2 |
| JAMES DILLON | 1 | 2 |
| David Kirske | 1 | 2 |
| Adam Craig | 1 | 2 |
| Pedro Beltran | 1 | 1 |
| Eli Wallace | 1 | 1 |
| Ness Bermingham | 1 | 1 |
| Geoff Meyerson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.